Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF5E6U)

• Drug Name: Tricyclic compound 9 Drug Info
• Synonyms: PMID27568917-Compound-Figure7(c)
• Cross-matching ID:
  PubChem CID: 135444572
  TTD Drug ID: DMF5E6U

Molecule-Related Drug Atlas

Drug(s) Targeting Receptor-interacting protein 1 (RIPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK2982772	DM7HNFV	Plaque psoriasis	EA90.0	Phase 2	[2]
DNL758	DM89D6C	Cutaneous lupus erythematosus	EB5Z	Phase 2	[3]
Eclitasertib	DM2O8VW	Ulcerative colitis	DD71	Phase 2	[4]
SAR443820	DMNCP7B	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[5]
GSK3145095	DM059OH	Pancreatic cancer	2C10	Phase 1/2	[6]
R552	DM5XCRQ	Nervous system paraneoplastic or autoimmune disorders	8E4A.1	Phase 1	[3]
DNL747	DMNSC0O	Alzheimer disease	8A20	Phase 1	[3]
DNL104	DMOSCQ9	Alzheimer disease	8A20	Phase 1	[7]
Tricyclic compound 10	DMV1RQX	N. A.	N. A.	Patented	[1]
Tricyclic compound 8	DMZI8GK	N. A.	N. A.	Patented	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Receptor-interacting protein 1 (RIPK1)	TTAIQSN	RIPK1_HUMAN	Inhibitor	[1]

References

• [1] Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [5] ClinicalTrials.gov (NCT05237284) A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension. U.S.National Institutes of Health.
• [6] Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
• [7] DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020 Feb;107(2):406-414.